ReviewPediatric nephrology (Berlin, Germany)2015
Tuberous sclerosis complex: the past and the future.
Review in Pediatric nephrology (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Folliculocystic and Collagen Hamartoma-An Unusual Dermatological Manifestation in a Case of Tuberous Sclerosis Complex.Indian dermatology online journal · 2026Article
- A unilateral presentation of papillary renal cell carcinoma in a pediatric patient with tuberous sclerosis complex: A rare case report.Urology case reports · 2026Article
- First recorded isolation ofRadiology case reports · 2025Article
- Analysis of Genotypes and Phenotypes in Chinese Patients With Tuberous Sclerosis Complex Harboring Novel Variants of TSC1 and TSC2 Genes.International journal of genomics · 2025Article
- Spontaneous angiomyolipoma rupture: A case of hemorrhagic shock and urgent embolization.Radiology case reports · 2024Article
- The roles of mTORC1 in parathyroid gland function in chronic kidney disease-induced secondary hyperparathyroidism: Evidence from male genetic mouse models and clinical data.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Review
- Dicer-Mediated mTORC1 Signaling and Parathyroid Gland Integrity and Function.Journal of the American Society of Nephrology : JASN · 2024Article
- Progressive Polycystic Kidney Disease in an Infant Girl With TSC2/PKD1 Contiguous Gene Syndrome.Cureus · 2024Article
- Regression of Cardiac Rhabdomyomas Producing a Severe Aortic Stenosis: Case Report and Discussion of the Literature.Diagnostics (Basel, Switzerland) · 2024Article
- Neurologic orphan diseases: Emerging innovations and role for genetic treatments.World journal of experimental medicine · 2023Review
- Child with intra cardiac masses and multiple seizure types. Rhabdomyoma, Tuberous sclerosis and possible Lennox-Gastaut syndrome - A rare case report.International journal of cardiology. Congenital heart disease · 2023Article
- Identification of an Electrogenic 2ClThe American journal of pathology · 2023Article
- Moments in autophagy and disease: Past and present.Molecular aspects of medicine · 2021Review
- Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Trends in survival and treatment of SEGA: National Cancer Database Analysis.Neuro-oncology practice · 2021Article
- Molecular diagnosis of an infant withHuman genome variation · 2020Article
- A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report.Orphanet journal of rare diseases · 2019Article
- Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.Pediatric nephrology (Berlin, Germany) · 2018Article
- Two novel TSC2 mutations in pediatric patients with tuberous sclerosis complex: Case report.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal lesions represent the second most significant cause of morbidity and mortality in patients with tuberous sclerosis complex (TSC). Recent advances in the understanding of the pathophysiology of TSC have led to the exploration of new potential therapeutic targets. Clinical trials with mammalian target of rapamycin (mTOR) inhibitors have demonstrated promising results for several indications, such as renal angiomyolipoma, subependymal giant cell astrocytoma, lymphangioleiomyomatosis and facial angiofibromas. Currently, there is a scarcity of natural history data and randomized, placebo-controlled clinical trials on TSC. Recently, however, recommendations for the diagnostic criteria, surveillance, and management of TSC patients have been updated. This review focuses on these novel recommendations and highlights the need for multidisciplinary follow-up of this multi-systemic disease.
Indexed as
Identifiers
25533384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.